| Previous Close | 4.80 |
| Open | 4.75 |
| Bid | 4.50 x 100 |
| Ask | 4.70 x 100 |
| Day's Range | 4.60 - 4.85 |
| 52 Week Range | 3.80 - 8.19 |
| Volume | 46,962 |
| Avg. Volume | 81,919 |
| Market Cap | 71.12M |
| Beta | 0.32 |
| PE Ratio (TTM) | -3.09 |
| EPS (TTM) | -1.52 |
| Earnings Date | Aug 8, 2017 - Aug 14, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.20 |
- PR Newswire•6 days ago
Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2a Clinical Trial
LEXINGTON, Mass., July 18, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that the last patient has completed dosing in Aldeyra's single-center, double-blind, randomized Phase 2a clinical trial of ADX-102 in Dry Eye Disease (DED). ADX-102 and other product candidates generated from Aldeyra's aldehyde trap platform sequester and facilitate the degradation of aldehydes, a class of endogenously generated pro-inflammatory mediators that are elevated in DED patients.
- PR Newswire•last month
Aldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting
The poster presentation will highlight the differentiated effects of ADX-102 on inflammatory cell migration and activation, lung function, and biochemical mediators of inflammation in a mouse model of endotoxin-induced lung injury. ADX-102, a novel aldehyde sequestering agent, has been shown in animal models to reduce pro-inflammatory cytokines, decrease tissue edema in allergic and contact dermatitis, reduce healing time and fibrosis in radiation-induced mucositis, and diminish inflammatory pain. In Phase 2 clinical trials in patients with noninfectious anterior uveitis and allergic conjunctivitis, two ocular inflammatory diseases, ADX-102 was statistically superior to control in reducing inflammation.
- 24/7 Wall St.•last month
Aldeyra Stumbles Over Mid-Stage Clinical Results
Aldeyra Therapeutics saw its shares slide on Wednesday after the company said its allergic conjunctivitis drug missed the primary endpoint in this Phase 2b trial.
